Tarsus Pharmaceuticals (TARS) Stock Price, News & Analysis

Company Overview

Tarsus Pharmaceuticals, Inc. is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders. The company leverages a multidisciplinary pipeline strategy, combining small‐molecule drug discovery with novel delivery approaches to optimize tissue penetration and minimize systemic exposure. Tarsus collaborates with clinical research sites across North America and Europe to execute its global development plans and intends to explore strategic partnerships for later‐stage commercialization and distribution.

Founded in 2018 and headquartered in Westlake Village, California, Tarsus Pharmaceuticals was established by a team of industry veterans with deep experience in ophthalmology, neurology and pharmaceutical development. The company’s leadership team includes seasoned executives with track records in launching ophthalmic products and navigating regulatory pathways. Tarsus maintains corporate offices in the United States and engages with regulatory authorities to advance its portfolio toward potential approval and market launch.

Key Stats

• Today's Range: $69.46 to $71.89
• 50-Day Range: $56.11 to $73.44
• 52-Week Range: $48.20 to $85.25
• Volume: 144,203 shs
• Average Volume: 735,379 shs
• Market Capitalization: $3.15 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $90.50
• Consensus Rating: Moderate Buy

Tarsus Pharmaceuticals Stock Analysis - MarketRank™

Tarsus Pharmaceuticals scored higher than 76% of companies evaluated by MarketBeat, and ranked 183rd out of 918 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Tarsus Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on 2 strong buy ratings, 4 buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

Tarsus Pharmaceuticals has a consensus price target of $90.50, representing about 26.1% upside from its current price of $71.77.

Amount of Analyst Coverage

Tarsus Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Tarsus Pharmaceuticals are expected to grow in the coming year, from ($2.06) to $0.57 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Tarsus Pharmaceuticals is -65.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Tarsus Pharmaceuticals is -65.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Tarsus Pharmaceuticals has a P/B Ratio of 9.08. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

15.12% of the float of Tarsus Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Tarsus Pharmaceuticals has a short interest ratio ("days to cover") of 7.49.

Change versus previous month

Short interest in Tarsus Pharmaceuticals has recently decreased by 0.32%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Tarsus Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Tarsus Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 4.1 / 5
• News Sentiment: 1.61

News Sentiment

Tarsus Pharmaceuticals has a news sentiment score of 1.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.89 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 12 news articles for Tarsus Pharmaceuticals this week, compared to 5 articles on an average week.

MarketBeat Follows

2 people have added Tarsus Pharmaceuticals to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Tarsus Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,452,821.00 in company stock.

Percentage Held by Insiders

9.64% of the stock of Tarsus Pharmaceuticals is held by insiders.

Percentage Held by Institutions

90.01% of the stock of Tarsus Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 8/27/2026
• Next Earnings (Estimated): 11/03/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:TARS
• CIK: 1819790
• Web: www.tarsusrx.com
• Phone: 949-409-9820
• Fax: N/A
• Employees: 50
• Year Founded: 2017

Price Target and Rating

• Average Price Target for Tarsus Pharmaceuticals: $90.50
• High Price Target: $100.00
• Low Price Target: $68.00
• Potential Upside/Downside: +26.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.78
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.09)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$66.42 million
• Net Margins: -7.67%
• Pretax Margin: -6.49%
• Return on Equity: -13.53%
• Return on Assets: -8.12%

Debt

• Debt-to-Equity Ratio: 0.21
• Current Ratio: 3.20
• Quick Ratio: 3.17

Sales & Book Value

• Annual Sales: $606.33 million
• Price / Sales: 5.17
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $7.90 per share
• Price / Book: 9.04

Miscellaneous

• Outstanding Shares: 43,883,000
• Free Float: 39,653,000
• Market Cap: $3.13 billion
• Optionable: Optionable
• Beta: 0.53